



Role of Interleukin-1 Super Family in Progression of Osteoarthritis

Amit Kumar¹, Md Arshad², Ajai Singh³, Asif Jafri², Sabir Ali³, Manish Yadav³, Suchit Swaroop^{1*}

¹Experimental and Public Health Laboratory, Department of Zoology, University of Lucknow, Lucknow – 226007, India; ephlablkouni@gmail.com

²Molecular Endocrinology Lab, Department of Zoology, University of Lucknow, Lucknow – 226007, India

³Department of Orthopaedics, King George Medical University, Lucknow – 226003, India

Abstract

Osteoarthritis (OA) is considered as multifactorial disorder characterized by erosion of articular cartilage, tightening of joint space, subchondral bone remodelling and internal synovial inflammation. OA reduces joint function progressively as a person gets older. The most important group of the cytokines or chemokines are pre-dominantly involving in the early progression of the disease includes IL-1, IL-6, IL-18 and TNF- α , etc. IL-1 family of cytokines are known to be strongest stimulus for progressive synthesis of Matrix Metallo Proteinases (MMPs). Large number of immune cells, chondrocytes and endothelial cells potentially secrete IL-1 with diverse effect on number of diseases. This review highlights the association of IL-1 family cytokine in OA.

Keywords: Cytokine, IL-1 family, Mode of Action, Osteoarthritis

1. Introduction

Osteoarthritis (OA) is a chronic disorder affecting knee, hip and other body joints, that frequently causes the reduction of joint functions and disability (Helmick *et al.*, 2008) (Fu *et al.*, 2015). OA is associated with reduced quality of life and economic burden on society today for middle age and older age people (Arliani *et al.*, 2014), an average 27 million people affected with arthritis in United State population (Lawrence *et al.*, 2008). OA is potentially irreversible disease (Wojdasiewicz *et al.*, 2014) that reduces range of motion of joints and characterized by increased catabolic rate of articular cartilage, sub chondral bone remodelling (Swellam *et al.*, 2010) and joint inflammation. The constantly increasing number of risk factors of OA includes obesity, aging, genetic predisposition, drug abuse, trauma and other systemic diseases (Richette *et al.*, 2003) which are responsible for up-regulation of different catabolic mediators like IL-1, IL-6, IL-15, IL-17 and IL-18 etc.

Over catabolism of cartilage destabilizes the joints and limits their functional ability (Choi *et al.*, 2013). Under normal state, joints maintain their homeostasis for synthesis and degradation of articular cartilage, whereas in osteoarthritic condition there is excessive degradation of cartilage occur. In OA, Chondrocytes are the only cells residing in cartilage which are targeted to number of pro-inflammatory mediators. IL-1 β in particular consider as a key mediator of cartilage damage and Extra Cellular Matrix (ECM) protein degradation through inducing the ECM degradative enzymes and other catabolic mediators, including IL-6, IL-8 etc (Guerne *et al.*, 1990) (Lotz *et al.*, 1992). Production of proteolytic enzymes in the extracellular space include collagenases such as matrix metalloproteinase-1, 13 (MMP-1, 13), aggrecanases (ADAMTS-4 &5, MMP-3) (Malfait *et al.*, 2002) and hyaluronidase etc. These destructive enzymes are causing breakdown of ECM component (Bau *et al.*, 2002; Lark *et al.*, 1997) (Nagase H and Kashiwagi M., 2003). Two chief glycoproteins are collagen type-II and aggrecans present

*Email: ephlablkouni@gmail.com

in ECM which established the strength of articular cartilage (Lee *et al.*, 2013). Final output of the cumulative effect of catabolic cytokines on ECM are result in synovitis, pain, joint remodelling, joint destruction, narrowing of joint space, inflammation at the site of destruction and finally loss of joint function that eventually leads to OA. IL-1 has been implicated in pathophysiology, immunological response at sub cellular level and also in pain induction (Barreto, A. and Braun, T. R., 2016). The complex mechanism of pathophysiology of the joint cartilage destruction has not been fully elucidated during osteoarthritic condition. The purpose of this review is to highlighting possible association of IL-1 with OA.

2. Interleukin (IL-1) Classification

Cytokines are nearly synthesized by all nucleated cells. These are small, soluble and membrane associated or chemically modified protein (glycoprotein) signal molecules having molecular weight of 8 to 40,000 Da (Banerjee, M. And Saxena, M., 2012). Cytokines are chemically diverse group and categorised into different forms such as interleukin, growth factor, interferon, chemokine and

Colony Stimulating Factor (CSF) etc. On the basis of their effect outcomes, cytokines have been broadly divided into two sub classes that are pro inflammatory mediators include IL-1, IL-6, IL-17, PGE-2, TNF- α , TGF- β and anti-inflammatory mediators such as IL-1RN, IL-4, IL-10, IL-13 etc. It has observed that the biosynthesis and secretion of these cytokines varies from disease to disease.

OA is destructive joint disease with elevated level of circulating inflammatory cytokines that have role in progression of disease and its etiological processes. Chondrodestructive inflammatory mediator is IL-1, primarily synthesized by chondrocyte cells (Loughlin *et al.*, 2002). It has reported in human and mice that IL-1 cytokine family consist of 11 different proteins naming from IL-1F1 to IL-1F11 that are encoded from 11 individual genes (Weber *et al.*, 2010). IL-1 super family consist of three main classes of related cytokines such as IL-1 α , IL-1 β and Interleukin-1 receptor antagonist (IL-1RN) whereas subtypes of IL-1Receptor, Interleukin-1 Receptor-Accessory Protein (IL-1R-AcP) and IL-18 also belongs to IL-1 super family (Banerjee, M. and Saxena, M., 2012) (Fig. 1). IL-RN was identified for counteracting the inflammatory effect of IL-1 without inducing downstream signal transduction (Grover *et al.*, 2006). Genes of




Fig. 1 Flow diagram of classification of IL-1 cytokine. Inteleukin-1alpha (IL-1 α); Inteleukin-1alpha (IL-1 β); Inteleukin-1receptor antagonist (IL-1RN or IL-1Ra); soluble IL-1RN (sRN-1RN); intra cellular IL-1RN type I and Type-II (icIL-1RNI, II); Inteleukin-1receptor (IL-1R); Inteleukin-1receptor Type-I(IL-1RI); Inteleukin-1receptor Type-II(IL-1RII); Interleukin-1 receptor accessory protein (IL-1RAcP); Interleukin-18 (IL-18).

these three secreted cytokines are situated on long arm of chromosome 2 which occupying <430Kb DNA elements (Loughlin *et al.*, 2002). Both the isoform IL-1 α and IL-1 β are structurally similar whereas they exhibit different level of gene expression. IL-1 α and IL-1 β both have pro-inflammatory properties and interact with same receptor. IL-1RN is considered as a natural antagonist that counteracts the proinflammatory properties of IL-1. IL-1RN exists both in secreted form (sIL-1RN) and intra cellular form (icIL-1RNI and icIL-1RNII).

3. IL-1 α

IL-1 α considered as key member of cytokine family that is released into the extra cellular space of chondrocyte under certain circumstances. Mature form of IL-1 α is derived from a precursor protein proIL-1 α (31KDa) which has N-terminal Nuclear Localising Sequence (NLS) signal

(Stevenson *et al.*, 1997). The maturation of IL-1 α (18KDa) occurs by removal of certain amino-terminal amino acid residues from a precursor protein. The maturation of IL-1 α is mediated by membrane bound cysteine protease called Calpain. Both the forms (proIL-1 α & IL-1 α) are biologically active to perform pro-inflammatory response (Banerjee, M. and Saxena, M., 2012). A detail account of cellular level of signal transduction triggered by IL-1 α is often under investigation. Somehow, it seems to have an impact on catabolism of joint cartilage.

4. IL-1 β

It is well recognised cytokine involved in progression of OA. The biosynthesis of active IL-1 β (17.5KDa) takes place by proteolytic digestion of immature proIL-1 β (31KDa). Proteolytic enzyme, *Caspase-1* has an important role in maturation of proIL-1 β (Dinarello, C.A., 2011). The




Fig. 2 Intracellular signal transduction of IL-1 β ligand and receptor complex downstream towards nucleus. Interleukin type-I receptor (IL-1RI); Interleukin type-II receptor (IL-1RII); Interleukin-1 receptor associated kinase (IRAK); TNF receptor associated factor-6 (TRAF-6); TAB1 is also known as mitogen activated protein kinase kinasekinase 7 inactivating protein 1(MAP3K7IP1) and TAB2 is also known as mitogen activated protein kinase kinasekinase 7 inactivating protein 2(MAP3K7IP2); TAK is a mitogen-activated protein kinase kinasekinase 7(MAP3K7); NF- κ B essential modulator/NF- κ B inhibitor kinase1,2(NEMO/IKK1,2); mitogen activated protein kinase (MAPK); basal transcription activating protein called activator protein-1 (AP-1).

proIL-1 β resides inside the cell whereas after maturation, it is secreted to extracellular environment of the secretory cell. IL-1 β , a well-studied cytokine involved in production of ECM proteinases primarily type-II collagenase and aggrecanase. These proteolytic enzymes are impaired the homeostasis of cartilage metabolism and cause anabolism shift towards catabolism. Apart from over catabolism, IL-1 β is also triggering the production of miRNAs in the extra cellular environment (Miyaki *et al.*, 2009). A recent study points out that the miRNAs are associated with breakdown of joint cartilage (Akhtar *et al.*, 2010).

5. IL-1RN

It directly inhibits inflammatory response of IL-1 cytokine without any cytosolic signal induction and transduction (Carter *et al.*, 1990). IL-1RN compete with IL-1 for recognising to IL-1R (Vigers *et al.*, 1997) thus making an antagonistic effect. IL-1RN has same binding affinity to IL-1R as in case of IL-1 α and IL-1 β (Dinarello, C.A., 1994). Neutrophils and macrophages produce a 16 to 18 IL-1RN (Granowits *et al.*, 1991). IL-1RN bears about 20 to 30 percent similarity with IL-1 α and IL-1 β in their acid residues composition of the protein chain. It has been reported in *in vivo* and *in vitro* studies that IL-1RN shows anti-inflammatory properties (McIntyre *et al.*, 1991). IL-1RN gene contains specific sequence repeats of 86 bp called Variable Numbers of Tandem Repeat (VNTR) in their polymorphic region of intron-2. Three potential transcription factors binding sites present in VNTR region may increase the level of expression of gene transcription and translation (Arnalich *et al.*, 2002).

6. IL-1R

It also belongs to IL-1 super family which interact with different members of IL-1 and regulates its activity. IL-1R is broadly divided into two forms, type-I (IL-1RI) and type-II (IL-1RII), whereas IL-1RII is further divided into two sub forms the soluble IL-1RII (sIL-1RII) and membrane bound IL-1RII (mIL-1RII) (Dinarello *et al.*, 1991). IL-1RI primarily helps in response to IL-1 ligand induced signal whereas IL-1RII could suppress the effect of IL-1.

7. IL-1R-AcP

It is a member of IL-1 super family which also called IL-1R3. It is a multi-pass membrane protein encoded

by *IL-1RAP-gene* (Gay, N. J. and Keith, F. J., 1997). Two different transcript variants of IL-1RAcP results from alternative splicing mechanism, a membrane bound form and a soluble form which are known to enhance the inflammatory property of IL-1 and help in subsequently signal transduction (Sims, J. E., 2002).

8. IL-18

It is recently defined member of the IL-1 super family that regulates the immune responses. It has reported that the its expression occur in various kind of cells such as synovial fibroblast, macrophases, dendric cells , kupffer cells, microglial cells etc (Conti, B., 1997; Prinz, M. and Hanisch U.K., 1999).

9. Association of IL-1 β with Osteoarthritis

IL-1 β is a pleotropic proinflammatory (Yuyan *et al.*, 2017) catabolic mediator that plays a pivotal role in pathogenesis of OA by ECM degradation. In OA, high level of IL-1 β is found in synovial membrane, synovial fluid, and cartilage etc. (Gordon *et al.*, 2008). It causes intracellular signal transduction by binding with IL-1 β receptor and induces inflammatory reactions. IL-1 β inducing kinins and prostanoids to trigger the nociceptive sensitization pathways. (Sommer, C., 2004; Hassett *et al.*, 2012).

IL-1 β induces various cell surface adhesion molecules such as Inter Cellular Adhesion Molecules (ICAM), L-selectin, Vascular Endothelial Cell Adhesion Molecule (VCAM) (Tsang *et al.*, 1997) which belongs to Immunoglobulin Super Family (IgSF). Apart from these functions, IL-1 β has shown to influence the release of other catabolic mediators such as IL-6, IL-8 and other small inflammatory factors such as chemokine ligand 5, also called RANTES (encoded by CCL5 gene), monocyte Chemoattractant Protein-1 (MCP-1) (Alaaeddine *et al.*, 2001; Villiger *et al.*, 2001) which exhibit additive or synergistic effect on cartilage breakdown.

Binding of IL-1 β to its Type-I receptor initiates signal transduction intargeted cell. The receptor IL-1RI also has binding affinity with IL-1 α and IL-RN (Symons *et al.*, 1995). IL-1 β also recognised by Type-II receptor and causes inactivation of ligand receptor complex thus no subsequent intracellular signal transduction occurs (Boraschi, D., 2013) (Fig. 2). It has been observed that chondrocyte

and synoviocyte cells shows expression of IL-1RI receptor in OA patients (Martel-Pelletier *et al.*, 1992; Sadouk *et al.*, 1995). After activation of IL-1RI, it binds with cytosolic Interleukin-1 Receptor Associated Kinase (IRAK) which subsequently activates TNF Receptor Associated Factor-6 (TRAF-6) through serine threonine kinase property and further recruits the TAK, TAB1 and TAB2 proteins. Furthermore, TAK phosphorylates the IKK1 & IKK2 and successively activate the NF- κ B (Kawai, T. and Akira, S., 2007). The final activation of cascade of cytosolic proteins result in expression of inflammatory mediators, matrix degrading enzymes, chemokines and other cell surface adhesion molecules (Roman-Blas J. A. and Jimenez S. A., 2006). The effects of IL-1 β on chondrocyte cells include production of matrix proteases, decrease in extracellular components production and other inflammatory cytokines production. MMPs are notable markers to destroy the ECM such as collagens. Both IL-1 β and TNF- α are responsible for expression of ADAMTS-4, whereas ADAMTS-5 production occurs constitutively without triggering of these cytokines (Koshy *et al.*, 2002; Verma, P. and Dalal, K., 2011). It has been described that IL-1 β inhibits receptor R-SMAD (Regulated-SMAD) mediated TGF- β signaling pathways. (Bauge *et al.*, 2008).

10. Summary

OA is a most complex disorder that difficult to describe pathophysiological events involved in disease development. Certain catabolic factors have supplementary role in degeneration of joint supportive muscles and cartilages that lead to joint inflammation, reduction in joint motion and pain. These symptoms irreversibly appear at higher frequencies as a person gets older (Bijlsma *et al.*, 2011; Madry, H. and Cucchiari, M., 2013).

OA exhibits progressive but gradual loss of ECM. IL-1 has considered as primary catabolic mediator in evolution of the disease by inducing synthesis of ECM degradative enzymes include MMP-1, MMP-13, Aggrecanases (ADAMTS-4 & 5, MMP-3), and hyaluronidase. These enzymes are responsible for degradation of most abundant glycoprotein such as collagen type-II. The production of proteolytic enzymes from chondrocyte is under the influence of IL-1 β induced intra cellular signaling down to nucleus. IL-1 β primarily induces signal transduction through binding with its type-I receptor whereas binding with type-II receptor leads to inactivation of the receptor and inhibition of further signal transduction. Number of

cytosolic kinases and transcription factors are positively associated in signal transmission towards nucleus. Apart from above role of IL-1 β , it also induces the nociceptive pathway and leads to pain.

Other studies suggest that IL-1 β has strong association in regulation of cytokine and expression of different growth factor in chondrocyte (Moos *et al.*, 1999). Previous studies do not clearly mention the role and significant association of IL-1 family cytokine in Osteoarthritis. Therefore, further study is needed to find out the exact role of IL-1 family cytokines in OA. It may be an unpredictable task to know the overall effect that will be positive.

11. Acknowledgments

The authors are thankful to Council of Scientific and Industrial Research, New Delhi, for financial support.

12. References

1. Akhtar, N., Rasheed, Z., Ramamurthy, S., Anbazhagan, A. N., Voss, F. R. and Haqqi, T. M. (2010) "MicroRNA-27b regulates the expression of matrix 13 in human osteoarthritis chondrocytes", *Arthritis Rheum*, **62**, 1361-1371. Crossref PMID:20131257 PMCID:PMC3139404
2. Alaeddine, N., Olee, T., Hashimoto, S., Creighton-Achermann, L. and Lotz, M. (2001) "Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation". *Arthritis Rheum*, **44**, 1633-1643. Crossref
3. Arliani, G., Astur, D. C., Yamada, R. K. F., Yamada, A. F., Miyashita, G. K., Mandelbaum, B. and Cohen. (2014) "Early osteoarthritis and reduced quality of life after retirement in former professional soccer players", *Clinics (Sao Paulo)*, **69**, 589-594. Crossref
4. Arnalich, F., Lopez-Maderuel, D., Codoceo, R., Lopez, J., Solis-Garrido, L. M., Capiscol, C., Fernandez-Capitan, C., Madero, R., Montiel, C. (2002) "Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis", *Clin Exp Immunol*, **127**, 331-336. Crossref
5. Banerjee, M. and Saxena, M. (2012) "Interleukin-1 (IL-1) family of cytokines: Role in type 2 Diabetes", *Clinica Chimica Acta*, **413**, 1163-1170. Crossref
6. Barreto, A. and Braun T. R. (2016) "A method to induce Interleukin-1 Receptor Antagonist Protein from autologous whole blood", *Cytokine*, **81**, 137-141. Crossref PMID:26994310

7. Bau, B., Gebhard, P. M., Haag, J., Knorr, T., Bartnik, E. and Aigner, T. (2002) "Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro", *Arthritis Rheum*, **46**, 2648-2657. Crossref PMID:12384923
8. Bauge, C., Attia, J., Leclercq, S., Pujol, J. P., Galera, P. and Boumediene, K. (2008) "Interleukin-1beta up-regulation of Smad7 via NF-kappaB activation in human chondrocytes", *Arthritis & Rheumatology*, **58**, 221-226. Crossref PMID:18163503
9. Bijlsma, J. W. J., Berenbaum, F. And Lafeber, F. P. J. G. (2011) "Osteoarthritis: an update with relevance for clinical practice", *The Lancet*, **337**, 2115-2126. Crossref
10. Boraschi, D. and Tagliabue, A. (2013) "The interleukin-1 receptor family", *Seminars in Immunology*, **25**, 394-407. Crossref PMID:24246227
11. Carter, D. B., Deibe, M. R.Jr., Dunn, C. J., Tomich, C. S., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F. and McEwan, R. N. (1990) "Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein", *Nature*, **344**, 633-638. Crossref PMID:2139180
12. Choi, Y. S., Park, J. K., Kang, E. H., Lee, Y. K., Kim, T. K., Chung, J. H., Zimmerer, J. M., Carson, W. E., Song, W. Y. and Lee, Y. J. (2013) "Cytokine signalling-1 suppressor is inducible by IL-1 beta and inhibits the catabolic effects of IL-1 beta in chondrocytes: Its implication in the paradoxical joint-protective role of IL-1 beta", *Arthritis Research & Therapy*, **15**, 191. Crossref PMID:24238405 PMCid:PMC3979110
13. Conti, B., Jahng, J. W., Tinti, C., Son, J. H. and Joh, T. H. (1997) "Induction of interferon-gamma inducing factor in the adrenal cortex", *J Biol Chem*, **272**, 2035-2037. Crossref PMID:8999896
14. Dinarello, C. A. and Thompson, R. C. (1991) "Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro", *Immunol Today*, **12**, 404-410. Crossref
15. Dinarello, C.A. (2011) "A clinical perspective of IL- β as the gatekeeper of inflammation", *Eur J Immunol*, **41**, 1203-1217. Crossref PMID:21523780
16. Dinarello, C. A. (1994) "The interleukin-1 family: 10 years of discovery", *FASEB J*, **8**, 1314-1325. PMID:8001745
17. Fu, M., Huang, G., Zhang, Z., Liu, J., Zhang, Z., Huang, Z., Yu, B. and Meng, F. (2015) "Expression profile of long noncoding RNAs in cartilage from knee osteoarthritis patients", *Osteoarthritis Cartilage*, **23**, 423-432. Crossref. PMID:25524778
18. Gay, N. J. and Keith, F. J. (1991) "Drosophila toll and IL-1 receptor", *Nature*, **351**, 355-356. Crossref PMID:1851964
19. Gordon, A., Kiss-Toth, E., Stockley, I., Eastell, R., and Wilkinson, M. J. (2008) "Polymorphisms in the interleukin-1 receptor antagonist and interleukin-6 genes affect risk of osteolysis in patients with total hip arthroplasty", *Arthritis & rheumatism*, **58**, 3157-3165. Crossref PMID:18821666
20. Granowits, E., Clark, B., Mancilla, J. and Dinarello, C. (1991) "Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin receptor", *J Bio Chem*, **266**, 14147-14150.
21. Grover, S., Tandon, B., Mishra, R. and Aggarwal, A. (2006) "Interleukin-1 receptor antagonist gene polymorphism in patients with rheumatoid arthritis in India", *Indian J. Med. Res*, **123**, 815-820. PMID:16885604
22. Guerne, P. A., Carson, D. A. and Lotz, M. (1990) "IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro", *J Immunol*, **144**, 499-505. PMID:2104896
23. Hassett, A. L., Epel, E., Clauw, D. J., Harris, R. E., Harte, S. E., Kairys, A., Buyske, S. and Williams, D. A. (2012) "Pain is associated with short leukocyte telomere length in women with fibromyalgia", *J Pain*, **13**, 959-969. Crossref PMID:23031395
24. Helmick, C. G., Felson, D. T., Lawrence, R. C., Gabriel, S., Hirsch, R., Kwoh, C. K., Liang, M. H., Kremers, H. M., Mayes, M. D., Merkel, P. A., Pillemer, S. R., Reveille, J. D. and Stone, J. H. (2008) "Estimates of the prevalence of arthritis and other rheumatic conditions in the United States", *Arthritis Rheum*, **58**, 15-25. Crossref PMID:18163481
25. Kawai, T. and Akira, S. (2007) "TLR signalling", *Seminars in Immunology*, **19**, 24-32. Crossref PMID:17275323
26. Koshy, P. J., Lundy, C. J., Rowan, A. D., Porter, S., Edwards, D. R., Hogan, A, Clark, I. M. and Cawston, T. E.(2002) "The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: A time-course study using real-time quantitative reverse transcription-polymerase chain reaction", *Arthritis and Rheum*, **46**, 961-967. Crossref PMID:11953973
27. Lark, M. W., Bayne, E. K., Flanagan, J., Harper, C. F., Hoerrner, L. A., Hutchinson, N. I., Singer, II., Donatelli, S. A., Weidner, J. R., Williams, H. R., Mumford, R. A. and Lohmander, L.S. (1997) Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritis, and rheumatoid joints. *J Clin Invest*, **100**, 93-106. Crossref PMID:9202061 PMCid:PMC508169
28. Lawrence, R. C., Felson, D. T., Helmick, C. G., Arnold, L. M., Choi, H., Deyo, R. A., Gabriel, S., Hirsch, R., Hochberg, M. C., Hunder, G. G., Jordan, J. M., Katz, J. N., Kremers, H. M. and Wolfe, F. (2008) "Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II", *Arthritis Rheum*, **58**, 26-35. Crossref PMID:18163497 PMCid:PMC3266664
29. Lee, A. S., Ellman, M. B., Yan, D., Kroin, J. S., Cole, B. J., Van Wijnen, A. J. and Im, H. J. (2013) "A current review

- of molecular mechanism regarding osteoarthritis and pain”, *Gene*, **527**, 440-447. Crossref PMID:23830938 PMCid:PMC3745800
30. Lotz, M., Terkeltaub, R. and Villiger, P. M. (1992) “Cartilage and joint inflammation.Regulation of IL-8 expression by human articular chondrocytes”, *J Immunol*, **148**, 466-473. PMID:1729366
 31. Loughlin, J., Dowling, B., Mustafa, Z. and Chapman, K. (2002) “Association of the Interleukin-1 Gene Cluster on Chromosome 2q13 with Knee Osteoarthritis”, *Arthritis & Rheumatism*, **46**, 1519–1527. Crossref PMID:12115182
 32. Madry, H. and Cucchiari, M. (2013) “Advances and challenges in gene-based approaches for osteoarthritis”, *The Journal of Gene Medicine*, **15**, 343-55. Crossref PMID:24006099
 33. Malfait, A.M., Lu, R.Q., Ljiri, K., Komiya, S. and Tortorella, M. D. (2002) “Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritis cartilage”, *J Biol Chem*, **227**, 22201-22208. Crossref PMID:11956193
 34. Martel-Pelletier, J., McCollum, R., DiBattista, J., Faure, M. P., Chin, J. A., Fournier, S., Sarfati, M. and Pelletier, J. P. (1992) “The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes: Identification as the type I receptor and analysis of binding kinetics and biologic function”, *Arthritis Rheum*, **35**, 530-540. Crossref
 35. McIntyre, K. W., Stepan, G. J., Kolinsky, K. D., Benjamin, W. R., Plocinski, J. M., Kaffka, K. L., Campen, C. C., Chizzonite, R. A. and Kilian, P. L. (1991) “Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro by IL-1 receptor antagonist and anti IL-1 receptor monoclonal antibody”, *J Exp Med*, **173**, 931-939. Crossref
 36. Miyaki, S., Nakasa, T., Otsuki, S., Grogan, S. P., Higashiyama, R., Inoue, A., Kato, Y., Sato, T., Lotz, M. K. and Asahara, H. (2009) “MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses”, *Arthritis Rheum*, **60**, 2723-2730. Crossref PMCid:PMC2806094
 37. Moos, V., Fickert, S., Muller, B., Weber, U. and Sieper, J. (1999) “Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage”, *J Rheumatol*, **26**, 870–879. PMID:10229409
 38. Nagase, H., and Kashiwagi, M., (2003) “Aggrecanases and cartilage matrix degradation”, *Arthritis Res Ther*, **5**, 94-103. Crossref PMID:12718749
 39. Prinz, M. and Hanisch, U. K., (1999) “Murine microglial cells produce and respond to interleukin-18”, *J Neurochem*, **72**, 2215-2218. Crossref PMID:10217305
 40. Richette, P., Corvol, M. and Bardin, T. (2003) “Estrogens, cartilage, and osteoarthritis”, *Joint Bone Spine*, **70**, 257-262. Crossref
 41. Roman-Blas, J. A. and Jimenez, S. A. (2006) “NF- κ B as a potential therapeutic target in osteoarthritis and rheumatoid arthritis”, *Osteoarthritis Cartilage*, **14**, 839-48. Crossref PMID:16730463
 42. Sadouk, M. B., Pelletier, J. P., Tardif, G., Kiansa, K., Cloutier, J. M. and Martel-Pelletier, J. (1995) “Human synovial fibroblasts coexpress IL-1 receptor type I and type II mRNA: The increased level of the IL-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor”, *Laboratory Investigation*, **73**, 347-55. PMID:7564267
 43. Sims, J. E. (2002) “IL-1 and IL-18 receptor, and their extended family”, *Curr Opin Immunol*, **14**, 117-122. Crossref
 44. Sommer, C. and Kress, M. (2004) “Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia”, *Neuroscience letters*, **361**, 184-187. Crossref PMID:15135924
 45. Stevenson, F. T., Turck, J., Locksley, R. M. and Lovett, D. H. (1997) “The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein”, *Proc Natl Acad Sci USA*, **94**, 508-13. Crossref
 46. Swellam, M., Mahmoud, M.S., Samy, N. and Gamal, A. A. (2010) “Potential influence of interleukin-1 receptor antagonist gene polymorphism on knee osteoarthritis risk”, *Disease Markers*, **28**, 299-305. Crossref PMID:20592454 PMCid:PMC3833698
 47. Symons, J. A., Young, P. R. and Duff, G. W. (1995) “Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 β precursor and loses affinity for IL-1 receptor antagonist”, *National Academy of Sciences of the United States of America*, **92**, 1714-1718. Crossref
 48. Tsang, Y. T., Neelamegham, S., Hu, Y., Berg, E. L., Burns, A. R., Smith, C. W. and Simon, S. I. (1997) “Synergy between L-selectin signaling and chemotactic activation during neutrophil adhesion and transmigration”, *J Immunol*, **159**, 4566-4577. PMID:9379058
 49. Verma, P. and Dalal, K. (2011) “ADAMTS-4 and ADAMTS-5: Key enzymes in osteoarthritis” *Journal of Cellular Biochemistry*, **112**, 3507-3514. Crossref PMID:21815191
 50. Vigers, G. P., Anderson, L. J., Caffes, P. and Brandhuber, B. J. (1997) “Crystal structure of the type I interleukin-1 receptor complexed with interleukin-1 β ”, *Nature*, **386**, 90-94. Crossref PMID:9062193
 51. Villiger, P. M., Terkeltaub, R. and Lotz, M. (1992) “Monocyte chemoattractant protein-1 (MCP-1) expression in human articular cartilage.Induction by peptide regulatory factors and differential effects of dexamethasone and retinoic acid”, *J Clin Invest*, **90**, 488-496. Crossref PMID:1365641 PMCid:PMC443125
 52. Weber, A., Wasiliew, P. and Kracht, M. (2010) “Interleukin-1 (IL-1) pathway”, *Sci Signal*, **3**. Crossref PMID:20086235
 53. Wojdasiewicz, P., Poniatowski, L. A. and Szukiewicz, D. (2014) “The Role of Inflammatory and Anti-Inflammatory

Cytokines in the Pathogenesis of Osteoarthritis”, *Mediators of Inflammation*, **2014**, 1-19. Crossref PMID:24876674
PMCID:PMC4021678

54. Yuyan, N., Rui, B., Zhenqun, Z., Yishan, W., Daihe, L., Yong, W. Sun, C., Sun, L., Zhang, B., Jin, T. and Liu, W.

(2017) “IL1R1 gene polymorphisms are associated with knee osteoarthritis risk in the Chinese Han population”, *Oncotarget*, **8**, 4228-4233.